Atreca (BCEL)
(Delayed Data from OTC)
$0.09 USD
0.00 (2.33%)
Updated May 31, 2024 03:49 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
Atreca, Inc. [BCEL]
Reports for Purchase
Showing records 141 - 159 ( 159 total )
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol. 7: Observations From Treatment Responsive Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Call With KOLs - Drs. Bob Darnell and Bill Robinson on March 12 at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Call With KOLs - Drs. Bob Darnell and Bill Robinson on March 12 at 12PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call with Dr. Bill Robinson on March 12 at 12 PM ET
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Deconvoluting Cancer Targets with Merck Research Partnership
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 4: B-cells May Aid In Checkpoint Inhibitor Therapy
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 5: B-Cells May Aid IO Responses - Implications for CRVS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Cancer Targets Resulting From An Active Anti-Tumor Immune Response
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
Q319: ATRC-101 First-In-Human Trial to Begin in 2020.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atreca, Inc.
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T